KRAS Human siRNA Oligo Duplex (Locus ID 3845)
CAT#: SR320806
KRAS (Human) - 3 unique 27mer siRNA duplexes - 2 nmol each
Need single siRNA in bulk?
Get a free quote
SR320806 is the updated version of SR302601.
CNY 4,090.00
货期*
4周
规格
Cited in 2 publications. |
Product images
经常一起买 (3)
KRAS mouse monoclonal antibody, clone OTI2C1 (formerly 2C1)
CNY 1,999.00
CNY 2,700.00
Specifications
Product Data | |
Purity | HPLC purified |
Quality Control | Tested by ESI-MS |
Sequences | Available with shipment |
Stability | One year from date of shipment when stored at -20°C. |
# of transfections | Approximately 330 transfections/2nmol in 24-well plate under optimized conditions (final conc. 10 nM). |
Note | Single siRNA duplex (10nmol) can be ordered. |
Reference Data | |
RefSeq | NM_004985, NM_033360, NM_001369786, NM_001369787 |
Synonyms | C-K-RAS; c-Ki-ras2; CFC2; K-Ras; K-RAS2A; K-RAS2B; K-RAS4A; K-RAS4B; KI-RAS; KRAS1; KRAS2; NS; NS3; RALD; RASK2 |
Components | KRAS (Human) - 3 unique 27mer siRNA duplexes - 2 nmol each (Locus ID 3845)Included - SR30004, Trilencer-27 Universal Scrambled Negative Control siRNA Duplex - 2 nmolIncluded - SR30005, RNAse free siRNA Duplex Resuspension Buffer - 2 ml |
Summary | This gene, a Kirsten ras oncogene homolog from the mammalian ras gene family, encodes a protein that is a member of the small GTPase superfamily. A single amino acid substitution is responsible for an activating mutation. The transforming protein that results is implicated in various malignancies, including lung adenocarcinoma, mucinous adenoma, ductal carcinoma of the pancreas and colorectal carcinoma. Alternative splicing leads to variants encoding two isoforms that differ in the C-terminal region. [provided by RefSeq, Jul 2008] |
Performance Guranteed | OriGene guarantees that at least two of the three Dicer-Substrate duplexes in the kit will provide at least 70% or more knockdown of the target mRNA when used at 10 nM concentration by quantitative RT-PCR when the TYE-563 fluorescent transfection control duplex (cat# SR30002) indicates that >90% of the cells have been transfected and the HPRT positive control (cat# SR30003) provides 90% knockdown efficiency. For non-conforming siRNA, requests for replacement product must be made within ninety (90) days from the date of delivery of the siRNA kit. To arrange for a free replacement with newly designed duplexes, please contact Technical Services at techsupport@origene.com. Please provide your data indicating the transfection efficiency and measurement of gene expression knockdown compared to the scrambled siRNA control (quantitative RT-PCR data required). |
Citations (2)
The use of this RNAi has been cited in the following citations: |
---|
EIF1AX and RAS mutations cooperate to drive thyroid tumorigenesis through ATF4 and c-MYC
,Krishnamoorthy, GP;Davidson, NR;Leach, SD;Zhao, Z;Lowe, SW;Lee, G;Landa, I;Nagarajah, J;Saqcena, M;Singh, K;Wendel, HG;Dogan, S;Tamarapu, PP;Blenis, J;Ghossein, R;Knauf, JA;Rätsch, G;Fagin, JA;,
Cancer Discov
,PubMed ID 30305285
[KRAS]
|
Ral A, via activating the mitotic checkpoint, sensitizes cells lacking a functional Nf1 to apoptosis in the absence of protein kinase C
,Ganapathy, S;Fagman, JB;Shen, L;Yu, T;Zhou, X;Dai, W;Makriyannis, A;Chen, C;,
Oncotarget
,PubMed ID 27741517
[KRAS]
|
Documents
Product Manuals |
FAQs |
SDS |
Customer
Reviews
Loading...